« A Startup's Post-Mortem |
| Nano-Drugs: Peaked, Or Maybe Past »
April 12, 2013
PPAR Delta For Cycling? I Think Not.
Now here's one that I didn't know about: a reader sends along word that the former clinical candidate GW501516 is enjoying some popularity on the black market among cyclists and other athletes.
I remember that compound well from the days when I did PPAR nuclear receptor research. It's the very model of a PPAR-delta ligand - GlaxoSmithKline had it in the clinic for some time, until it slowly disappeared from their roster. In 2007, the Evans lab at the Salk Institute published a paper suggesting that the compound increased endurance, and that sent it right into the athletic underworld. I have no idea if it does what its users want, but I do know that I wouldn't touch the stuff. The PPAR compounds have a very, very wide range of effects, and unraveling those proved to be very difficult indeed. Long-term effects of a compound like this one are unknown - all we know is that GSK dropped it from the clinic, and that could well have been for tox. Taking this stuff to gain some time in a bicycle race is sheer foolhardiness.
+ TrackBacks (0) | Category: Chemical News
POST A COMMENT
- RELATED ENTRIES
- The Antibiotic Gap: It's All of the Above
- Phenotypic Assays in Cancer Drug Discovery
- Neratinib Comes Through For Puma
- How Many Biopharma Employees Would Rather Be Working Somewhere Else?
- The Broad Gets $650 Million For Psychiatric Research
- Put Them in Cells and Find Out
- The Hep C Field Gets Nastier By the Minute
- Allergan Twists and Turns